Edition:
United States

Pfizer Inc (PFE)

PFE on New York Consolidated

35.45USD
19 Sep 2017
Change (% chg)

$-0.10 (-0.28%)
Prev Close
$35.55
Open
$35.66
Day's High
$35.66
Day's Low
$35.35
Volume
15,692,147
Avg. Vol
18,948,612
52-wk High
$35.84
52-wk Low
$29.83

Chart for

About

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business... (more)

Overall

Beta: 0.97
Market Cap(Mil.): $211,704.70
Shares Outstanding(Mil.): 5,955.13
Dividend: 0.32
Yield (%): 3.60

Financials

  Industry Sector
P/E (TTM): -- 31.87 16.18
EPS (TTM): -- -- --
ROI: -- 15.15 14.60
ROE: -- 16.38 13.87

BRIEF-Pfizer announces outcome of FDA advisory committee meeting for Sutent

* Pfizer announces outcome of FDA advisory committee meeting for Sutent in patients at high risk of recurrent renal cell carcinoma after surgery

1:22pm EDT

Pfizer, Astellas prostate cancer drug promising in late-stage trial

Pfizer Inc and Japan's Astellas Pharma Inc said on Thursday their blockbuster prostate cancer drug met the main goal of a key study that tested it for treating the disease in its early stages.

Sep 14 2017

UPDATE 3-Pfizer, Astellas prostate cancer drug promising in late-stage trial

* Pfizer's shares up 1.8 pct (Adds analysts' comments, details on drug's potential market; updates shares)

Sep 14 2017

CORRECTED-UPDATE 2-Pfizer, Astellas prostate cancer drug succeeds key trial

Sept 14 Pfizer Inc and Japan's Astellas Pharma Inc said on Thursday their prostate cancer drug met the main goal of a trial testing it for a more common form of the disease.

Sep 14 2017

Pfizer, Astellas prostate cancer drug clears late-stage trial

Pfizer Inc and Astellas Pharma Inc said on Thursday their drug to treat a type of prostate cancer met the main goal in a late-stage trial.

Sep 14 2017

CORRECTED-Pfizer, Astellas prostate cancer drug clears late-stage trial

Sept 14 Pfizer Inc and Astellas Pharma Inc said on Thursday their drug to treat a type of prostate cancer met the main goal of improving overall survival in a late-stage trial.

Sep 14 2017

BRIEF-Astellas Pharma and Pfizer say positive top-line results from phase 3 prosper trial of XTANDI (enzalutamide)

* Co and Pfizer Inc announced that the Phase 3 PROSPER trial evaluating XTANDI®(enzalutamide) plus androgen deprivation therapy (ADT) versus ADT alone in patients with non-metastatic (M0) CastrationResistant Prostate Cancer (CRPC) met its primary endpoint of improved metastasis-free survival (MFS)

Sep 14 2017

BRIEF-Pfizer, Astellas report positive top-line results from phase 3 PROSPER trial of XTANDI

* Pfizer and Astellas announce positive top-line results from phase 3 prosper trial of XTANDI (enzalutamide) in patients with non-metastatic castration-resistant prostate cancer

Sep 14 2017

BRIEF-Pfizer says ‍results indicated a improvement in OS for patients

* Pfizer Inc - ‍results indicated a numerical improvement in OS for patients treated with first-line xalkori compared with chemotherapy​

Sep 11 2017

RPT-UPDATE 1-Germany's Merck hires JP Morgan to sell consumer health

FRANKFURT/LONDON, Sept 8 Germany's Merck KGaA has hired JP Morgan to sell its consumer health business, which includes brands such as Seven Seas vitamins and could be worth around $4.5 billion.

Sep 11 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $135.22 -0.16
Novartis AG (NOVN.S) CHF82.75 +0.65
Merck & Co., Inc. (MRK.N) $65.95 -0.04
Roche Holding Ltd. (ROG.S) CHF244.80 +1.10
Roche Holding Ltd. (RO.S) CHF245.70 +1.70
Abbott Laboratories (ABT.N) $51.41 -0.67
Bayer AG (BAYGn.DE) €109.90 -0.60
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €82.25 +0.73
AstraZeneca plc (AZN.L) 4,774.00 +64.00

Earnings vs. Estimates